Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial
Clément Massonnaud, Nathan Peiffer‐Smadja, Pascal Poignard, Simon Jamard et autres